Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
作者信息
Cohen Jeffrey I
机构信息
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
J Infect Dis. 2017 Mar 15;215(6):844-846. doi: 10.1093/infdis/jix006.
Abstract
摘要
相似文献
1
Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
J Infect Dis. 2017 Mar 15;215(6):844-846. doi: 10.1093/infdis/jix006.
2
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
Vaccine. 2013 Dec 9;31(51):6136-43. doi: 10.1016/j.vaccine.2013.06.081. Epub 2013 Jul 9.
3
[Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
Vopr Virusol. 2010 Jan-Feb;55(1):35-40.
4
Genital herpes vaccine shows limited promise.
JAMA. 2000 Oct 18;284(15):1913-4.
5
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
J Infect Dis. 2003 Feb 15;187(4):542-9. doi: 10.1086/374002. Epub 2003 Feb 7.
6
Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
Vaccine. 2018 May 11;36(20):2842-2849. doi: 10.1016/j.vaccine.2018.03.075. Epub 2018 Apr 11.
7
Immunology. Painful failure of promising genital herpes vaccine.
Science. 2010 Oct 15;330(6002):304. doi: 10.1126/science.330.6002.304.
8
Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
J Infect Dis. 2000 Jan;181(1):335-9. doi: 10.1086/315208.
9
Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
Virology. 2016 Jan 15;488:61-7. doi: 10.1016/j.virol.2015.10.033. Epub 2015 Nov 21.
10
Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Herpes. 2004 Apr;11(1):12-7.
引用本文的文献
1
A review of HSV pathogenesis, vaccine development, and advanced applications.
Mol Biomed. 2024 Aug 29;5(1):35. doi: 10.1186/s43556-024-00199-7.
2
Triterpenes and Phenolic Compounds from with Antiviral Activity against Herpes Simplex Virus Type-2.
Plants (Basel). 2022 Mar 13;11(6):764. doi: 10.3390/plants11060764.
3
A Novel High-Intensity Focused Ultrasound-Treated Herpes Simplex Virus 2 Vaccine Induces Long-Term Protective Immunity against Lethal Challenge in Mice.
mSphere. 2020 Dec 23;5(6):e00859-20. doi: 10.1128/mSphere.00859-20.
4
Alphaherpesvirus Vaccines.
Curr Issues Mol Biol. 2021;41:469-508. doi: 10.21775/cimb.041.469. Epub 2020 Sep 23.
5
Successful application of prime and pull strategy for a therapeutic HSV vaccine.
NPJ Vaccines. 2019 Aug 1;4:33. doi: 10.1038/s41541-019-0129-1. eCollection 2019.
6
Antibody response to feline herpesvirus-1 vaccination in healthy adult cats.
J Feline Med Surg. 2020 Apr;22(4):329-338. doi: 10.1177/1098612X19845702. Epub 2019 May 13.
7
Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.
J Infect Dis. 2018 Oct 20;218(11):1691-1699. doi: 10.1093/infdis/jiy372.
8
A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2785-2793. doi: 10.1080/21645515.2017.1323604. Epub 2017 May 8.
本文引用的文献
1
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.
J Infect Dis. 2017 Mar 15;215(6):856-864. doi: 10.1093/infdis/jix004.
2
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189.
3
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.
4
An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
Hum Vaccin Immunother. 2016 Dec;12(12):3079-3088. doi: 10.1080/21645515.2016.1221872.
5
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.
Clin Microbiol Rev. 2016 Jan;29(1):149-61. doi: 10.1128/CMR.00043-15.
6
Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines".
Vaccine. 2014 Mar 20;32(14):1561-2. doi: 10.1016/j.vaccine.2014.01.052. Epub 2014 Jan 28.
7
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection.
Nature. 2013 May 23;497(7450):494-7. doi: 10.1038/nature12110. Epub 2013 May 8.
8
The challenge of developing a herpes simplex virus 2 vaccine.
Expert Rev Vaccines. 2012 Dec;11(12):1429-40. doi: 10.1586/erv.12.129.
9
ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.
J Infect Dis. 2012 Apr 1;205(7):1100-10. doi: 10.1093/infdis/jis019. Epub 2012 Feb 20.
10
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4.
Zotero 插件